Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker
By Angelica Peebles,
CNBC
| 02. 21. 2025
Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday, marking the end of the Bluebird’s fall from the one of the buzziest biotech firms to one that was on the cusp of running out of money.
Bluebird’s shareholders will receive $3 per share with the possibility of getting another $6.84 a share if Bluebird’s gene therapies reach $600 million in sales in any 12-month period by the end of 2027. Bluebird shares closed at $7.04 on Thursday. They fell 40% on Friday after the company announced the sale.
For more than thirty years, Bluebird has been at the forefront of creating one-time treatments that promised to cure genetic diseases. At one point, Bluebird’s market cap hovered around $9 billion as investors bought into the idea that the company could find success with its gene therapies. It’s fallen under $41 million after the company faced several scientific setbacks, separated its cancer work into another company and fell into financial despair.
The turning point came in 2018, when Bluebird...
Related Articles
Gray wolf by Jessica Eirich via Unsplash
“I’m not a scarcity guy, I’m an abundance guy”
– Colossal co-founder and CEO Ben Lamm, The New Yorker, 4/14/25
Even the most casual consumers of news will have seen the run of recent headlines featuring the company Colossal Biosciences. On March 4, they announced with great fanfare the world’s first-ever woolly mice, as a first step toward creating a woolly mammoth. Then they topped that on April 7 by unveiling one...
By Katrina Northrop, The Washington Post | 04.06.2025
photo via Wikimedia Commons licensed under CC by 3.0
China's most infamous scientist is attempting a comeback. He Jiankui, who went to jail for three years after claiming he had created the world's first genetically altered babies, says he remains...
By Kevin Davies, Genetic Engineering & Biotechnology News | 03.27.2025
Around 2018–19, there was not a bigger science and ethical story than the debate over heritable human genome editing (HHGE) and the scandal over the “CRISPR babies.” The scientist, He Jiankui, who attempted to engineer the germline of human embryos...
By Megan Molteni, Stat | 03.28.2025
WASHINGTON — Keith Joung knows better than a lot of people what, exactly, it might require to prove to regulators and patients that CRISPR could be safely used to alter the genome of a human embryo. If, of course, society...
